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HIV-1 viral protein R (Vpr) is predominantly localized to the nucleus and plays an important role for viral preintegration
complex import into the nucleus. In this study, we investigated the influence on subcellular localization of Arg residues in the
C-terminus of Vpr. Consistent with previous studies, about 90% of the cells manifested diffuse nuclear staining in the
Vpr-expressed cells. Besides diffuse nuclear staining, punctate perinuclear staining, and punctate cytoplasmic staining were
also observed in the immunofluorescence studies. Deletion of the Ser-Arg-Ile-Gly residues (amino acids 79–82; SRIG) had
no effect on the Vpr localization. However, deletion of the Arg-Gln-Arg-Arg residues (amino acids 85–88; RQRR) resulted in
a smooth perinuclear staining pattern. Substitution of five Arg residues with Asn (amino acids 80, 85, 87, 88, and 90; R3 N5)
resulted in a diffuse cytoplasmic staining. Subcellular fractionation analyses support the immunofluorescence staining
results. These findings indicate that the C-terminal Arg residues of HIV-1 Vpr play an important role for Vpr nuclear
localization. All the Vpr mutants were appropriately expressed, exhibited no significant defect on the protein stability, and
were incorporated efficiently into virus-like particles. Both SRIG and R3 N5 mutants lost their cell cycle arrest activities and
the RQRR deletion only exhibited a low level of cell arrest activity. Therefore, the Arg residues in the HIV-1 Vpr C-terminus
are important for Vpr nuclear localization and cell cycle arrest , but had no effect on protein stability or Vpr incorporation into
virus-like particles. © 1998 Academic Press
Key Words: Vpr; HIV-1; nuclear localization and cell cycle.
INTRODUCTION
In addition to the basic functions encoded by gag, pol,
and env, the human immunodeficiency virus type 1
(HIV-1) genome includes at least six additional genes
(tat, rev, vpr, vpu, vif, and nef) with distinct regulatory
roles (Cullen and Green, 1990; Subbramanian and Co-
hen, 1994). HIV-1 vpr encodes a protein [viral protein R
(Vpr)] of 96 amino acids (Wong-Staal et al., 1987). The
role of Vpr in virus replication in vitro is cell type depen-
dent. Vpr is dispensable for replication of HIV and SIV in
transformed monocytoid and T cell lines (Dedera et al.,
1989; Ogawa et al., 1989), but expression of vpr products
is essential for virus replication in primary macrophages
(Balliet et al., 1994; Campbell and Hirsch, 1997; Cohen et
al., 1990; Dedera et al., 1989; Fletcher et al., 1996; Nishino
et al., 1991). The role of Vpr in HIV pathogenesis is still
not clear. It was reported that SIVmac Vpr is important for
the development of an AIDS-like disease in rhesus ma-
caques (Lang et al., 1993). However, other studies have
resulted in ambiguous results (Gibbs et al., 1995; Hoch et
al., 1995). Although there are no conserved vpr mutations
in long-term survivors, a mother and child pair study has
shown that a correlation between disease progression
and vpr gene mutations, especially mutations in the
39-end of vpr gene (Wang et al., 1996). Furthermore, risk
group-associated differences in HIV-1 Vpr sequences
are also located in the C-terminal region (Kuiken et al.,
1996). Another Vpr function, which may be related to HIV
pathogenesis, is its ability to increase the mutation rate
about fourfold (Mansky, 1996). Therefore, Vpr could be an
important factor for HIV-1 diversity, which increases the
chance for the virus to escape immune system or drug
attack. Therefore, the Vpr product, especially the C-ter-
minal region of Vpr, could play an important role in HIV
pathogenesis and AIDS development.
Levy et al. first have shown that Vpr expression in rhab-
domyosarcoma cells prevented cell proliferation and in-
duced differentiation (Levy et al., 1993). Other groups have
also observed that, in vitro, Vpr prevents the establishment
of chronically infected HIV-1 producer cell lines, suggesting
that cell cycle arrest could be one of the important roles for
Vpr in HIV-1 replication (Rogel et al., 1995). It has been
suggested that the ability of Vpr to block cell division is by
blocking the mitotic cell cycle in the G2 phase (Di Marzio et
al., 1995; Emerman, 1996; Mahalingam et al., 1995c; Re et
al., 1995; Rogel et al., 1995). Vpr-induced cell cycle arrest in
the G2 phase is conserved from yeast (Zhang et al., 1997;
Zhao et al., 1996) to primate lentiviruses (Planelles et al.,
1996; Stivahtis et al., 1997).
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One of the most important characteristics of Vpr is its
ability to facilitate transport of the viral preintegration
complex into the nucleus of nondividing cells in conjunc-
tion with a nuclear localization sequence present in the
Gag MA protein (MA-NLS) (Heinzinger et al., 1994). Vpr
facilitates replication in primary macrophages, consis-
tent with the presence of Vpr in virions and its localiza-
tion in the nucleus of transfected cells (Balotta et al.,
1993; Connor et al., 1995; Hattori et al., 1990; Westervelt
et al., 1991). As the result, Vpr is required for replication
in macrophages, which do not divide, but is dispensable
in dividing cells, such as activated peripheral blood
mononuclear cells (Connor et al., 1995).
Since our first report on the nuclear localization of Vpr
(Lu et al., 1993), several investigators have confirmed
that Vpr is a nuclear protein (Mahalingam et al., 1995a;
Yao et al., 1995; Zhao et al., 1994b). It has been sug-
gested that the karyopherin pathway is not involved in
Vpr nuclear localization or that the interaction of Vpr with
another protein with a NLS accounts for Vpr import into
the nucleus (Gallay et al., 1996). Recently, the direct
interaction of Vpr with karyopherin-a has been demon-
strated (Popov et al., 1997). However, a typical NLS se-
quence from SV40 large T antigen could not block Vpr
binding with karyopherin-a although it did block MA
association with karyopherin-a, suggesting that the Vpr
binding site(s) on karyopherin-a is different from that of
MA. Sequence analysis showed that the C-terminus of
Vpr is highly basic, a common feature of NLS. Removal of
amino acids 78–96, which contain the basic residues
region, greatly impaired Vpr nuclear localization (Lu et
al., 1993). However, Zhao et al. reported that deletion of
either amino acids 88–96 or amino acids 78–87 did not
affect nuclear localization of Vpr (Zhao et al., 1994a).
Furthermore, the mutagenic analyses by both groups
have demonstrated an important role in nuclear localiza-
tion for the a-helix near the N-terminus, although no
NLS-like sequence is present in that region (Mahalingam
et al., 1995b; Yao et al., 1995).
In this study, the roles of the carboxyl-terminal argin-
ine-rich sequence of Vpr in cellular localization, cell cycle
effects, and the Vpr export and incorporation into virus
particles were specifically studied. Our data suggested
that the arginine residues in the C-terminal region are
important for Vpr localization and cell arrest, but have no




Our previous results have shown that the C-terminal
region of HIV-1 Vpr is important for the Vpr nuclear
localization. For further investigation of Vpr nuclear
targeting, we have generated deletion and substitution
mutants of the basic domain of Vpr (Fig. 1). This region
contains five to seven Arg residues, depending on the
HIV-1 isolate. Five Arg residues, found at positions 80,
87, 88, 90, and 95, are highly conserved among HIV-1
isolates, whereas Arg residues at positions 77 and 85
are less well conserved and are substituted with Gln
in about 50% of strains. To analyze the role of these
Arg residues in Vpr localization and cell cycle arrest
functions, three mutants were generated. The first one
is a deletion mutant of Ser-Arg-Ile-Gly at residues
79–82 (SRIG) and designated as pTM-VPRSRIG. Another
mutant is a deletion of Arg-Gln-Arg-Arg at residues
85–88, designated as pTM-VPRRQRR (Fig. 1). The third
mutant is a substitution mutant in which five of the Arg
codons (positions 80, 85, 87, 88, and 90) are substi-
tuted with Asn codons and is designated as pTM-
VPRR3N5 (Fig. 1).
Stability of Vpr
The stability of HIV-2 Vpr protein was shown to be
important for its cell cycle arrest activity (Kewalramani et
al., 1996). Although some studies suggested that the
protein expression level is not critical for Vpr cell cycle
arrest function, other studies in the yeast system have
suggested that the protein expression level does affect
the cell growth (Macreadie et al., 1995). To compare the
expression and stability of wild-type Vpr with that of the
mutant proteins, 293-tet-induced cells were transfected
with pUHD-Vpr and its relevant mutants for 24 h. The
cells were then metabolically labeled with 100 mCi/ml of
[4,5-3H]leucine for 12 h and chased in the absence of
radioisotope for 30 min. The cells were harvested at
different time points and immunoprecipitations were car-
ried out (Fig. 2A). The proportion of Vpr protein or mutant
protein at different time points was determined by laser
densitometry. Wild-type Vpr and the mutant proteins
were expressed at similar levels (Fig. 2A). It is interesting
that the half-lives of VprSRIG and VprRQRR were about 20 h
while the half-life for the wild-type Vpr protein was only
about 11 h (Fig. 2B). VprR3N5 was a less stable protein
with a half-life of 7 h, similar to that of wild-type Vpr (Fig.
FIG. 1. The C-terminal sequence of wild-type and mutant Vpr pro-
teins. The C-terminal sequence from pNL4-3 Vpr used in this study is
shown on the top. The other sequences are those for the deletion and
substitution mutants. LR, leucine-rich domain.
415C-TERMINAL Vpr Arg RESIDUES
2B). Thus, all the mutant are expressed well and are
relatively stable in the cells.
Influence on Vpr localization of mutations of C-
terminal basic sequences
To study cellular localization, Vpr or its relevant mutant
gene products were expressed in the Hela cells using
the vaccinia virus expression system, stained with anti-
Vpr antiserum and a secondary fluorescein isothyocya-
nate (FITC)-conjugated antibody, and examined by con-
focal microscopy. Intensive immunofluorescence was
observed in cells transfected with Vpr constructs (Figs.
3A–3D), but no fluorescence was observed in cells trans-
fected with vector alone (Fig. 3E). Similar to our previous
findings (Lu et al., 1993), the wild-type Vpr and VprSRIG
displayed a variety of staining patterns, including diffuse
nuclear (Fig. 3A), punctate perinuclear (Fig. 3B), and
punctate cytosolic staining. Most of the cells exhibited
more than one staining pattern, which were quantitated
from 50 randomly selected positive cells. Sixty-six per-
cent of the cells had strong diffuse nuclear staining,
whereas 24% exhibited weaker nuclear staining. Seven-
ty-two percent of the cells had punctate perinuclear
staining, and 86% of the cells showed punctate cytosolic
staining.
VprSRIG showed no significant difference from wild-
type Vpr in the immunofluorescence staining pattern
(data not shown). In contrast to the variable staining
pattern of wild-type Vpr or VprSRIG, almost all of the
VprRQRR-transfected cells displayed smooth perinuclear
staining (Fig. 3C). Weak diffuse nuclear staining was
present in a small proportion of these cells. The VprR3N5-
transfected cells displayed exclusively diffuse cytosolic
staining (Fig. 3D), distinct from the cytosolic staining
pattern of wild-type Vpr which was more condensed.
These results indicate that the Arg residues in the C-
terminus of Vpr influenced the protein’s localization.
Subcellular fractionation
In the immunofluorescence staining analysis, HIV-1
Vpr and its mutant proteins showed several distinct
staining patterns, including diffuse nuclear staining,
perinuclear staining, and cytoplasmic staining. To con-
firm our immunostaining results and study whether the
Vpr protein may be associated with distinct cellular com-
partments, subcellular fractionation was carried out. Vpr
or its relevant mutant gene products were expressed in
the Hela cells using the vaccinia virus expressing sys-
tem. The infected/transfected cells were labeled for 16 h
with [4,5-3H]leucine, harvested, and fractionated into
membrane, cytosol, nuclear wash, nucleoplasm, and
chromatin and matrix as described under Material and
Methods. No wild-type Vpr protein was found in the
cytosolic fractions and the membrane fractions (Fig. 4A).
When the nuclear pellet was washed with the buffer
containing Triton X-100, 13% of Vpr protein was detected
in the nuclear wash fraction. When the pellet was
washed further with the buffer containing NP-40, 36% of
the Vpr was in the nucleoplasm fraction. However, the
majority of the protein (51%) was located in the chromatin
and nuclear matrix fraction (Fig. 4A). These results are
similar to our previous observations, indicating that the
HIV-1 Vpr protein is mainly located in the nucleus and
may be associated with some nuclear components (Lu et
al., 1993).
Deletion of the SRIG sequence did not affect the lo-
calization of the Vpr protein in the subcellular fraction-
ation analysis. A similar ratio of the Vpr SRIG protein was
found in each fraction compared to wild-type Vpr (Fig.
4A). The proportion of the RQRR deletion mutant in each
fraction was different, with more protein detected in
nuclear wash (30%) and nucleoplasm (37%) fractions and
less protein found in the chromatin/nuclear matrix (33%)
FIG. 2. Stability of Vpr and its mutant proteins. (A) Vpr and its relevant
mutants expressed from pUHD in 293-tet-induced cells. After metabolic
labeling, cells were chased with complete DMEM and harvested at 0,
4, 8, 12, and 24 h, respectively. The cells were lysed with RIPA buffer
and immunoprecipitated with anti-Vpr antiserum. (B) The relative inten-
sity of Vpr and its mutant proteins at each time point were determined
by laser densitometry, and plotted as the percentage of protein versus
that measured at 0 h of chase.
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fraction (Fig. 4A). When all five of the Arg residues were
changed to Asn, the majority of the protein (80%) was
detected in the nuclear wash fraction and very little
protein was detected in the nucleoplasm (10%) and al-
most no signal was found in the chromatin/nuclear ma-
trix fraction (Fig. 4A).
The vaccinia expression system has been widely used
to express Vpr, but vaccinia-induced cytotoxicity could
have affected the subcellular distribution. To avoid the
vaccinia cytotoxicity effects, 293-tet-induced cells were
transfected with pUHD-VPR, pUHD-VPRSRIG, pUHD-
VPRRQRR, and pUHD-VPRR3N5, respectively, and ana-
lyzed as described under Material and Methods. No
wild-type Vpr protein was found in the cytosolic fractions
and the membrane fractions. Eleven percent of Vpr pro-
tein was detected in the nucleoplasm fraction, while the
majority of the protein (89%) was located in the chromatin
and nuclear matrix fraction (Fig. 4B). A similar ratio of the
VprSRIG protein was found in each fraction compared to
wild-type Vpr (Fig. 4B). The proportion of the RQRR de-
letion mutant in each fraction was different, with more
protein detected in nuclear wash (9%) and less protein
found in the chromatin/nuclear matrix (60%) fraction (Fig.
4B). Similar to the observations in the vaccinia expres-
sion system, the majority of VprR3N5 (90%) was detected
in the nuclear wash fraction and very little protein was
detected in the nucleoplasm and almost no signal was
found in the chromatin/nuclear matrix fraction (Fig. 4B).
Vpr and its relevant mutants have similar localization
patterns in the both expression systems. Although the
majority of the VprR3N5 is located outside of the nucleus,
it is not in a soluble form in the cytoplasm, suggesting
that the protein may be associated with a cellular struc-
ture, or compartment in the cytoplasm. To rule out con-
tamination during the cell fractionation, bacterial b-ga-
lactosidase, characterized as a soluble protein in the
cytosolic fraction, was coexpressed with Vpr or its mu-
tant proteins in these assays. More than 90% of the
b-galactosidase activity was found in the cytosol, as
measured by enzymatic assay. Less than 5% of the b-ga-
lactosidase activity was detected in the postnuclear
wash or membrane fractions, and no detectable activity
was found in the purified nuclei (data not shown). There-
fore, the Arg residues in the C-terminal region of the Vpr
protein are important for localization.
Virion incorporation of Vpr mutants
To examine virion incorporation, the vaccinia virus
expression system was used, since it has been shown to
faithfully reproduce the properties of retrovirus assembly
(Spearman et al., 1994). Our previous report showed that
expression of p55gag alone resulted in the formation of
virion-like particles with a density of 1.16–1.17 g/ml, sim-
ilar to that of HIV-1 particles. Coexpression of Gag and
Vpr resulted in the export of Vpr from transfected cells
and incorporation into these virus-like particles (Lu et al.,
1993).
When Vpr and the mutants were coexpressed with
p55gag in BSC40 cells, no significant differences were
FIG. 3. The influence of basic residues on Vpr localization. Hela cells were infected with vTF7-3 and transfected with (A, B) pTM-VPR, (C)
pTM-VPRRQRR, (D) pTM-VPRR3N5, or (E) pTM vector. Two different staining patterns of wild-type Vpr are shown in (A) and (B). (A) Representative of
cells with diffuse nuclear and focal perinuclear staining. (B) Representative of cells with punctate perinuclear or punctate cytoplasmic staining.
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noted in the level of expression of Vpr mutants compared
to the wild-type protein (Fig. 5, lanes 1 to 4). In the
absence of Gag expression, none of the Vpr protein was
exported to the medium (data not shown). In contrast,
coexpression of Gag resulted in Vpr export in all cases
(Fig. 5, lanes 5–8). Densitometric analysis indicated that
the incorporation ratio of mutant Vpr protein was either
similar to or slightly better than that of wild-type Vpr,
suggesting that the mutants have no defect on Vpr in-
corporation into virus-like particles.
Cell cycle arrest analysis of Vpr and its mutant
proteins
One of the functions of HIV-1 Vpr is to cause cell cycle
arrest in G2/M phases, which has been suggested to
relate to HIV pathogenesis. Therefore, we further ex-
plored whether mutations at the Arg residues would
affect the Vpr cell cycle arrest function (Fig. 6). pUC12,
pcDNA-VPR, pcDNA-VPRSRIG, pcDNA-VPRRQRR, and
pcDNA-VPRR3N5 were transfected into 293 cells, and the
cell cycle effect was analyzed by propidium iodide stain-
ing. In the previous reports, Vpr was shown to cause the
cell cycle arrest in the G2/M phase of 293 cells. In
support of this, our results showed that about 75% of Vpr
expressing cells were in the G2/M phase (Fig. 6B); in
contrast to pUC12-transfected cells, the negative control,
had about 20% of the cells in the G2/M phase (Fig. 6A) (Di
Marzio et al., 1995). It has been reported that the H(F/
S)RIG sequences are important for cell cycle arrest in
yeast and further confirmed its importance in mammalian
cell expression systems using synthetic peptides (Ma-
creadie et al., 1995, 1996). However, there are no data
with full-length Vpr protein that supports this conjecture
in the mammalian cells. Our results indicated that dele-
tion of SRIG abolished Vpr cell cycle arrest, suggesting
that the SRIG sequence is important for cell cycle arrest
(Fig. 6C). When the pcDNA-VPRRQRR was transfected into
293 cells, a partial effect on cell cycle was observed
which was about 20% of the activity of that of wild-type
Vpr (Fig. 6D). The pcDNA-VPRR3N5 showed no cell cycle
FIG. 4. Subcellular distribution of transiently expressed Vpr and its C-terminal mutant proteins. (A) Vpr was expressed from pTM-VPR, -VPRSRIG,
-VPRRQRR, or -VPRR3N5 using vaccinia expression system. (B) Vpr was expressed from pUHD-VPR, -VPRSRIG, -VPRRQRR, and -VPRR3N5 in the
293-tet-induced cells. In both A and B, the cells were labeled with [4,5-3H]leucine and fractionated into membranes (Mem), cytosol (Cyto), postnuclear
wash (NW), nucleoplasm (NuP), and chromatin and nuclear matrix (Chx/MA) and immunoprecipitated with anti-Vpr antiserum. The SDS–PAGE
analyses are shown in the bottom panel and the proportion of Vpr in each subcellular fraction, determined by laser densitometry, are shown in the
top panel.
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arrest (Fig. 6E). These results suggest that the Arg resi-
dues in the C-terminus are important for Vpr cell cycle
arrest.
DISCUSSION
Although deletion of the entire C-terminal region of Vpr
resulted in a protein with reduced stability (Lu et al.,
1993; Mahalingam et al., 1995a; Paxton et al., 1993; Yao et
al., 1995), the more restricted mutations used in this
study had no apparent effect on Vpr expression, stability,
or virus-like particle incorporation. In contrast, mutation
in the N-terminal a-helix, which disrupted Vpr localization
in the nucleus, also disrupted virion incorporation, sug-
gesting that these mutations could have global effects on
protein folding (Mahalingam et al., 1995a; Yao et al.,
1995). Our results correspond with previous observa-
tions that the C-terminal sequence is dispensable for
virion packaging (Lu et al., 1993; Mahalingam et al.,
1995a; Paxton et al., 1993; Yao et al., 1995). No significant
packaging defect was observed with the three Vpr mu-
tants described in this study in spite of their different
nuclear localization patterns, suggesting that the nuclear
localization of Vpr protein is not related to Vpr packaging.
Our previous report documented that Vpr is predomi-
nantly localized in the nucleus (Lu et al., 1993). In addi-
tion, a small portion of Vpr was localized in a different
cellular compartment. In this study, we demonstrated
that wild-type Vpr has several staining patterns revealed
by confocal microscopy, including diffuse nuclear, punc-
tate perinuclear, and punctate cytoplasmic staining. The
ability of Vpr to localize to several cellular compartments
may explain its ability to mediate various biological ac-
tivities, including the ability to target the viral preintegra-
tion complex to the nucleus, arrest the cell cycle in the
G2 phase, and its ability to act as an ion channel (Piller
et al., 1996).
The Vpr C-terminal sequence plays a role in Vpr nu-
clear localization, since Vpr with a C-terminal deletion of
residues 76–96 is located in the cytoplasm (Lu et al.,
1993). Recently, the N-terminal a-helix has been reported
to be important for Vpr nuclear localization (Mahalingam
et al., 1995a). The VprSRIG mutant had a similar localiza-
tion in both the immunofluorescence and the cellular
fractionation experiments to that of wild-type Vpr. How-
ever, the VprRQRR protein localization was changed. Most
of the protein was detected in the perinuclear region by
immunofluorescence staining and cellular fractionation.
About half of the protein was detected in the nuclear
wash or nucleoplasm fractions. The immunofluores-
cence experiments were performed at 4 h postinfection
to minimize the vaccinia cytopathic effects, while the
fractionation experiments were done after 16 h of label-
ing the transiently expressing cells. Therefore, the immu-
nofluorescence results are representative of highly ex-
pressed Vpr protein at an early stage of expression,
while the transient expression of Vpr in either HeLa cells
using vaccinia expression system or in the 293-tet-in-
duced cells was representative of stable Vpr protein in
FIG. 5. Incorporation of wild-type and mutant Vpr into virus-like particles. BSC40 cells were infected with vTF7-3 and cotransfected with pTM-GAG
and pTM-VPR, pTM-VPRSRIG, pTM-VPRRQRR, or pTM-VPRR3N5. Metabolically labeled proteins from cell lysates or cell supernatants were immuno-
precipitated with antisera to Vpr and Gag before SDS–PAGE analysis.
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these cells. The RQRR deletion Vpr may only partially
affect localization. As a result, more VprRQRR protein is
located in the perinuclear region and less protein was
found in the chromatin/matrix fractions. Substitution of
Arg at amino acids 80, 85, 87, 88, and 90 with Asn
residues impaired nuclear localization, further indicating
that the Arg residues are important for Vpr localization.
Although the VprR3N5 protein was detected in the cyto-
plasm in the immunofluorescence studies, the protein is
not free in the cytoplasm because the majority of the
protein is found in the nuclear wash fraction, suggesting
that most of the protein is either in, or associated with,
cellular components. Therefore, to study the Vpr local-
ization, especially the protein located in the cytoplasm, a
cellular fractionation assay should be performed. Previ-
ous attempts to identify the nuclear localization signal
from Vpr have not been successful. For example, the
C-terminal basic region of Vpr fused with b-galactosi-
dase could not drive majority of fusion protein into the
nucleus, like a typical NLS, but did change the fusion
protein cellular localization, and more LacZ activity was
detected in the nuclear fraction (including nuclear wash,
nucleoplasm, and chromatin and matrix) compared to the
cytosol fraction, suggesting that the C-terminal region of
FIG. 6. Cell cycle analysis for Vpr and its mutants. 293 cells were cotransfected with pcDNA-Vpr or its relevant mutants and pTK-Hgy. The DNA
profiles of hygromycin-resistant cells were analyzed 3 days after transfection. The numbers represent one of three experiments that all had similar
results.
420 ZHOU, LU, AND RATNER
Vpr could regulate protein localization (data not shown).
This result provides further support to the contention that
the C-terminal of Vpr is important for protein localization.
In vitro, Vpr causes cell cycle arrest in the G2 phase
(Di Marzio et al., 1995; He et al., 1995; Jowett et al., 1995;
McCarthy, 1995; Planelles et al., 1996; Re et al., 1995;
Stivahtis et al., 1997; Zhao et al., 1996). Since the C-
terminal truncated Vpr could not cause cell cycle arrest
(Di Marxio et al., 1995), this suggests that the C-terminal
region of the Vpr protein is necessary for this activity.
More detailed studies have shown that the H(F/S)RIG
sequences in the C-terminal region are critical for cell
cycle arrest, and peptides which contain these se-
quences could arrest cells, suggesting that the H(F/
S)RIG sequence is sufficient for cell cycle arrest function
(Macreadie et al., 1996; Macreadie et al., 1995; Zhang et
al., 1997). Single Arg residue mutations at position 80
abolished Vpr cell cycle arrest function, suggesting that
this residue also plays an important role in the cell cycle
arrest (Di Marzio et al., 1995). VprSRIG could not arrest the
cell cycle although the localization and virion incorpora-
tion abilities of this protein were similar to wild-type Vpr.
This result further suggests that the SRIG sequence is
one of the cell cycle arrest functional domains. It is very
interesting that less of the RQRR mutant protein is in the
nucleus than wild-type Vpr, and this mutant only partially
affects cell cycle arrest. In contrast, the VprR3N5 protein
was located outside of the nucleus and had no cell cycle
arrest activity. It is not clear whether this defect is due to
the protein localization change. It has been suggested
that the interaction of Vpr with cellular proteins may be
related to Vpr cell cycle arrest (Planelles et al., 1996;
Selig et al., 1997; Stivahtis et al., 1997). The cellular
localization changes of the mutant Vpr proteins may
affect their interactions and in turn affect the cell cycle
arrest activity of this protein.
MATERIALS AND METHODS
DNA constructs
The vpr gene of HIV-1 NL4-3 was cloned into pTM-3 to
generate pTM-VPR, as previously described (Lu et al.,
1993). To analyze the role of these Arg residues in Vpr
localization, three mutants were generated. The first one
is a deletion mutant of codons 81–84 (Ser-Arg-Ile-Gly),
designated as pTM-VPRSRIG (Fig. 1). This was done by
inserting the oligonucleotides 59-TCGAC ATG TTACT
CGA CAGAGGAGA GCGCG CAAT-39 and 59-TCGAC
TAAGA TCTAC TGGCT CCATTG CGCGC TCTCCTCTG
TCG AGTAA CAT G-39 at the unique SalI site at position
5785. HIV-1 nucleotides 5558–5869, encompassing the
mutant vpr gene were obtained by PCR using primers
59-AATAC CATGG AACAA GCCCC CCAGA AGA-39 and
59-GATGC TTCCA GGGAT CCGTC TAGGA TCTAC TG-39.
The reaction product was digested with NcoI and BamHI
and cloned into pTM-3. The second mutant is a deletion
mutant of codons 85–88 (Arg-Gln-Arg-Arg), designated
as pTM-VPRRQRR (Fig. 1). This was done by inserting the
oligonucleotides 59-TCGAC ATAGC AGAAT AGGCG
TTACT GCGCG CAAT-39 and 59-TCGAC TAAGA TCTAC
TGGCT CCATTG CGCGC AGTAA CGCCT ATTCT GCTAT
G-39 at the unique SalI site at position 5785 located in the
39 end of the vpr open reading frame, corresponding to
amino acid residue 76. HIV-1 nucleotides 5558–5869,
encompassing the mutant vpr gene were obtained by
PCR using primers 59-AATAC CATGG AACAA GCCCC
CCAGA AGA-39 and 59-GATGC TTCCA GGGAT CCGTC
TAGGA TCTAC TG-39. The reaction product was digested
with NcoI and BamHI and cloned into pTM-3. The third
mutant is a substitution mutant in which five of the Arg
codons (positions 80, 85, 87, 88, and 90) were substituted
with Asn codons and is designated as pTM-VPRR3N5
(Fig. 1). This was constructed by ligation of the following
four oligonucleotides into the proviral clone at the SalI
site: 59-TCGAC ATAGC AACAT AGGCG TTACT AACCA
G-39, 59-TGTTC TGGTT AGTAA CGCCT ATGTT GCTAT
G-39, 59-AACAA CGCAA ACAAT GGAGC CAGTA GATCT
TAG-39, and 59-TCGAC TAAGA TCTAC TGGCT CCATT
GTTTG CGT-39. The resultant mutated vpr gene was
cloned into pTM as described above.
The pcDNA-VPR, -VPRRQRR, -VPRR3N5, and -VPRSRIG
were constructed by ligation of the NcoI/BamHI frag-
ments from pTM-VPR, pTM-VPRRQRR, pTM-VPRR3N5 and
pTM-VPRSRIG into HindIII/BamHI sites of pcDNA3.1 (In-
vitrogen) after blunted HindIII and NcoI sites with Klenow
DNA polymerase I.
To construct the tet-induced plasmids, pTM-VPR and
its relevant mutant plasmids were digested with NcoI,
treated with Klenow DNA polymerase I, and then di-
gested with BamHI. The purified DNA fragments were
cloned between the EcoRI and BamHI sites of pUHD-
10-3 (kindly provided by Dr. H. Bujard; Gossen and Bu-
jard, 1992) after blunting the EcoRI site with Klenow DNA
polymerase I to obtain pUHD-VPR, pUHD-VPRSRIG,
pUHD-VPRRQRR, and pUHD-VPRR3N5.
All the plasmids were confirmed by DNA sequence
using the Sequenase Version 2.0 DNA sequencing kit
(USB) based on the dideoxynucleotide termination
method (Sanger et al., 1977). The sequence analyses
were carried out with the DNA Striker program.
Cell lines and culture
293, BSC40, and HeLa cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal calf serum, 100 U of penicillin/
streptomycin per milliliter. 293-tet-induced cell lines were
obtained by transfecting pUHD-17-3, which encodes the
reverse Tet-responsive transcriptional activator (kindly pro-
vided by Dr. H. Bujard; Gossen and Bujard, 1992) into 293
cells and the highly inducible clones were selected as
described elsewhere (Gossen and Bujard, 1992). The cell
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lines were maintained in DMEM supplemented with 10%
heat-inactivated tetracycline-free fetal calf serum (Clon-
tech), 100 U of penicillin/ml, 100 mg of streptomycin/ml, and
200 mg/ml of G418. To induce gene expression, 2 mg/ml of
doxycycline (Sigma) was added.
DNA transfection
Cells were grown to 80% confluence on 60-mm-diam-
eter culture dishes and transfected with lipofectamine as
recommended by Gibco-BRL. Briefly, solution A was pre-
pared by adding 3 mg plasmid DNA into 150 ml of Opti-
MEM I reduced-serum medium (Gibco-BRL) and solution
B by adding 9 ml of lipofectamine into 150 ml of Opti-MEM
I reduced-serum medium. Solution A and B were mixed
gently and left for 15–30 min at room temperature. Mean-
while, 1.2 ml of Opti-MEM I reduced-serum medium was
added to plates after washing two times with serum-free
medium. The A1B mixture was then added to the plate.
After incubation for 4 h or overnight, 1.5 ml DMEM con-
taining 20% fetal calf serum (FCS) was added. After 5 h
incubation, the medium was replaced with DMEM with
10% FCS and antibiotics. The transfected cells were
either analyzed at 48 to 72 h after transfection or se-
lected with G418 to generate stable cell lines.
Subcellular fractionation
Infection–transfection protocol for the vaccinia virus
expression system was as described elsewhere (Fuerst
et al., 1986). Briefly, Hela cells were grown to 90% con-
fluence on 60-mm-diameter plates, infected for 1 h at
37°C with vTF7-3, a vaccinia virus expressing T7 RNA
(Fuerst et al., 1986) at a multiplicity of infection (m.o.i.) of
10, and then cotransfected with pTM-VPR constructs and
pTM-LacZ at the ratio of 20:1 by the lipofectamine trans-
fection method. Four hours after transfection, the cells
were labeled for 16 h with 1.5 ml of leucine-free DMEM
containing 100 mCi of [4,5-3H]leucine per milliliter. The
cells were then chased with DMEM with 10% FCS for 4 h.
Labeled cells were fractionated into membrane, cytoso-
lic, postnuclear, nucleoplasm, and chromatin and nu-
clear matrix fractions as previously described (Lu et al.,
1993). The purity of the nuclear fractions (nucleoplasm
and chromatin and nuclear matrix) was examined by
using a control cytosolic protein, b-galactosidase, ex-
pressed in the same cells from pTM-LacZ. To express
Vpr in 293-tet-induced cells, the cells were transfected
with pUHD-VPR, pUHD-VPRSRIG, pUHD-VPRRQRR, and
pUHD-VPRR3N5, respectively, and labeled with 100 mCi
of [4,5-3H]leucine per milliliter for 16 h. The cells were
then harvested, fractionated, and the amount of Vpr in
each fraction determined as described above.
Immunoprecipitation
Equivalent proportions (v/v) of each of the subcellu-
lar fractions were mixed with an equal volume of 23
SDS-PAGE sample buffer (0.125 M Tris–HCl, pH 6.8,
20% glycerol, 10% v/v 2-mercapoethanol, 4% w/v SDS)
and boiled for 10 min. After spinning briefly, the sample
was diluted 40-fold with RIPA buffer without SDS (1%
v/v Triton X-100, 0.5% w/v deoxycholate, and 0.2 mM
PMSF in PBS). An aliquot was taken for scintillation
counting to determine relative labeled protein content.
Immunoprecipitation was performed by the addition to
equivalent proportions (v/v) of each of the subcellular
fractions to 5 ml of anti-Vpr antiserum. Incubation was
continued overnight at 4°C. Twenty microliters of im-
mobilized proteinA (50% v/v in PBS) beads (rproteinA,
Repligen Co.) were added, and the mixture was incu-
bated for 15 to 120 min at 4°C. Immunoprecipitates
were collected at 500g for 30 s at room temperature
and washed three times with RIPA buffer and once
with PBS. The beads were resuspended in 30 ml of
SDS–PAGE sample buffer treated at 100°C for 10 min
before loading onto 15% denatured polyacrylamide
gel. The gels were infused with 1 M sodium salicylate
for 45 min, dried on filter paper, and exposed to a
XAR-5 film (Kodak) at 280°C with intensifying screens.
Band intensities were determined by densitometry.
Immunofluorescence
To study the Vpr localization, Hela cells were
seeded on glass coverslips (Nunc) at a density of 1 3
105 cells per well in a 24-well plate and were infected
for 60 min with vTF7-3. Then the pTM-VPR, pTM-
VPRSRIG, pTM-VPRRQRR, pTM-VPRR3N5, or pTM vector
alone was transfected using lipofectamine. The cells
were harvested 4 h after transfection and fixed with
2.5% (w/v) glutaraldehyde for 15 min in order to mini-
mize the cytopathic effects caused by vaccinia virus
infection. After permeabilizing the cells with 0.2% (v/v)
Triton X-100 for 6 min at room temperature, the cells
were then blocked for nonspecific binding of immuno-
globulin by incubation for 30 min with PBS containing
5% (w/v) nonfat dry milk and 0.1% (v/v) Tween 20.
Slides were then incubated with rabbit anti-Vpr anti-
body (1:100 in PBS with 0.5% Tween 20 and 1% bovine
serum albumin) for 1 h at room temperature. The cells
were washed several times with 0.3% (v/v) Triton X-100
in PBS and incubated at 4°C for 60 min with FITC-
conjugated goat anti-rabbit immunoglobulin G to de-
tect Vpr. The slides were washed extensively with PBS
and mounted in Aqua mount solution (Lerner Lab)
containing 2.5% 1,4-diazobicyclo-[2,2,2]-octane (Sigma)
to prevent photobleaching of the FITC signal. Slide prep-
arations were examined on a Nikon fluorescence micro-
scope equipped with appropriate filters and a microflex
UFX camera system. Photographs were prepared by
using Kodak T-MAX film, push processed to ASA 3200.
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Particle incorporation
BSC40 cells were infected with vTF7-3 at a m.o.i. of 2
and cotransfected with the Vpr expression plasmids to-
gether with pTM-GAG, containing the entire p55gag se-
quence from HXB2 (Lu et al., 1993). Four hours after
transfection, the cells were metabolically labeled for 20 h
with 2 ml of leucine-free DMEM containing 10% dialyzed
fetal calf serum and 100 mCi of [4,5-3H]leucine/ml. The
culture supernatants were removed and centrifuged at
2500 rpm for 15 min in a Beckman GS-6 rotor to remove
cellular debris. Particles were concentrated by sedimen-
tation through a 20% sucrose cushion prepared in PBS at
25,000 rpm for 90 min at 4°C in an SW28.1 rotor. Particles
were resuspended in 23 SDS–PAGE sample buffer as
described above. The Gag and Vpr proteins in the su-
pernatants or cell lysates were immunoprecipitated over-
night at 4°C with both the anti-Gag and anti-Vpr antisera
as described earlier.
Flow cytometry
293 cells were cotransfected with different pcDNA-
VPR and its relevant mutants plasmids and pTK-hygro-
mycin (5:1) by lipofectamine methods following the pro-
cedure recommended by the manufacturer (Gibco-BRL).
Twenty-four hours after transfection, 200 mg/ml of hygro-
mycin was added. Forty-eight hours after transfection,
the cells were trypsinized and selected in the 200 mg/ml
of hygromycin for another 24 or 48 h. Cells were pre-
pared for cytometry as described (Ausubel et al., 1989).
Briefly, the hygromycin resistant cells (about 0.5 3 106)
cells were pelleted and resuspended into 0.1 ml of PBS
with 1% of glucose and then fixed by the addition of 1 ml
of 70% ethanol and incubated at 4°C for at least 15 hours.
The fixed cells were pelleted then resuspended into 0.1
ml of PBS with 1% glucose and then treated with 0.5 ml
of PBS containing 1% glucose, RNase A (50 U/ml), and
propidium iodide (PI) (50 mg/ml) for at least 60 min before
flow cytometric analysis with the Cellquest program
(Becton Dickinson Immunocytometry Systems).
Polymerase chain reaction (PCR)
PCR reactions consisted of 50 mM KCl, 10 mM Tris-
HCl (pH 9.0), 0.1% Triton X-100, 1.5 mM MgCl2, 20 pmol of
each primer, template plasmid DNA, 0.25 mM dNTP, and
2.5 U of Taq polymerase. The reaction was carried out in
a total volume of 50 ml. The first cycle was performed at
94°C 3 min, 72°C 2 min, 50°C 1 min 30 s, followed by 30
cycles of 94°C 45 s, 72°C 2 min, and 55°C 1 min. The last
cycle extension time at 72°C was 10 min.
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